Hadox Research Labs · Science Intelligence
We watch the research landscape, compare papers with fair peers, read the full text and publish the receipts. No journal logo, citation count or model gets the last word alone.
Current truthThe ascendance engine is still building history. This edition is editorially selected, not algorithmically declared “rising.”
Comparison universe1,138 current candidates across 41 age, field and article-type cohorts.
Evidence gateEvery public dossier was read from an authorised full body. Abstract-only records remain ineligible.
As of25 Jul 2026
This public, sanitized index unites the observatory with Hadox's reviewed dossiers. Bibliographic metadata and measured signal states are visible; abstracts and source text are not.
Tracking is not endorsement. A row means Hadox is monitoring the paper or has completed a public dossier. Radar states appear only when measured against age-, field- and article-type peers; no metric is invented for editorial selections.
Read the selection method| Paper | Field | Radar state | Attention | Next review | Hadox |
|---|---|---|---|---|---|
| CAR T-cell therapy for patients with relapsed or refractory marginal zone lymphoma The Lancet · 2026-03-01 · 10.1016/s0140-6736(26)00094-2 | Oncology Research article | Baseline Candidate · 1 signal point | 0 citations Cohort 26% · 19 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Claire Calderwood: integrated health screening for tuberculosis The Lancet · 2026-03-01 · 10.1016/s0140-6736(26)00516-7 | Infectious Diseases Research article | Baseline Candidate · 1 signal point | 0 citations Cohort 25% · 16 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Closing the adolescent health financing gap: the Global Financing Facility The Lancet · 2026-03-01 · 10.1016/s0140-6736(26)00320-x | General Health Professions Research article | Baseline Candidate · 1 signal point | 0 citations Cohort 36% · 18 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Department of Error The Lancet · 2026-03-01 · 10.1016/s0140-6736(26)00467-8 | Cardiology and Cardiovascular Medicine Research article | Baseline Candidate · 1 signal point | 0 citations Cohort 29% · 17 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Department of Error The Lancet · 2026-03-01 · 10.1016/s0140-6736(26)00421-6 | Cardiology and Cardiovascular Medicine Research article | Baseline Candidate · 1 signal point | 0 citations Cohort 29% · 17 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Efficacy and safety of LEVI-04 in patients with osteoarthritis of the knee: a randomised, double-blind, placebo-controlled, phase 2 trial The Lancet · 2026-03-01 · 10.1016/s0140-6736(26)00131-5 | Medicine Research article | Baseline Candidate · 1 signal point | 3 citations Cohort 75% · 181 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Fundamental PEPFAR reform risks a period of structural vulnerability in the HIV response The Lancet · 2026-03-01 · 10.1016/s0140-6736(26)00369-7 | Infectious Diseases Research article | Baseline Candidate · 1 signal point | 3 citations Cohort 75% · 16 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Genomic atlas of Bifidobacterium infantis and B. longum informs infant probiotic design Cell · 2026-03-01 · 10.1016/j.cell.2026.01.007 | Agricultural and Biological Sciences Research article | Baseline Candidate · 1 signal point | 9 citations Cohort 71% · 17 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Giant DNA viruses encode a hallmark translation initiation complex of eukaryotic life Cell · 2026-03-01 · 10.1016/j.cell.2026.01.008 | Immunology Research article | Baseline Candidate · 1 signal point | 7 citations Cohort 69% · 13 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Health justice The Lancet · 2026-03-01 · 10.1016/s0140-6736(25)02163-4 | Health Research article | Baseline Candidate · 1 signal point | 0 citations Cohort 40% · 5 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Hijacking ERAD for targeted degradation of transmembrane proteins Cell · 2026-03-01 · 10.1016/j.cell.2026.01.018 | Cell Biology Research article | Baseline Candidate · 1 signal point | 5 citations Cohort 95% · 10 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Human genetics guides the discovery of CARD9 inhibitors with anti-inflammatory activity Cell · 2026-03-01 · 10.1016/j.cell.2025.12.013 | Cancer Research Research article | Baseline Candidate · 1 signal point | 4 citations Cohort 50% · 5 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Human-specific features of the cerebellum and ZP2-regulated synapse development Cell · 2026-03-01 · 10.1016/j.cell.2026.02.014 | Developmental Neuroscience Research article | Baseline Candidate · 1 signal point | 1 citations Cohort 30% · 5 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Identification of Or5v1/Olfr110 as an oxylipin receptor and anti-obesity target Cell · 2026-03-01 · 10.1016/j.cell.2025.12.016 | Neuroscience Research article | Baseline Candidate · 1 signal point | 6 citations Cohort 81% · 21 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
| Lessons from the history of the Uganda Virus Research Institute The Lancet · 2026-03-01 · 10.1016/s0140-6736(26)00470-8 | Infectious Diseases Research article | Baseline Candidate · 1 signal point | 0 citations Cohort 25% · 16 peers · signal 2026-07-21 | 2026-08-04 assessed 2026-07-21 | Tracking Not yet a public dossier |
These are the exact visual editions already shared by Hadox. Each one now has a canonical source, immutable assets and a visible workflow state; publication history never substitutes for scientific review.
01
The source is identified, but no authorised full body is available for Hadox review yet.
02
Published edition linked to a full-text Hadox evidence dossier.
03
This official-source story is awaiting the institutional evidence workflow.
Historical copy retained; correction logged in the workflow.
Today, 0 papers have enough history for a momentum score and 0 public dossiers were selected by an open ascendance gate. That is not a failure to hide; it is the calibration state.
current paper assessments from Crossref + Openalex
cohorts split by paper age, article type and discipline
baseline · 1 watch · 0 rising
01Observe attention against fair peers.
02Wait for enough history to measure velocity.
03Read the authorised full paper and map every claim.
04Make a separate editorial decision and publish the evidence.